Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Thompson Medical

This article was originally published in The Tan Sheet

Executive Summary

Thompson Medical: Submits results from a new double-blind placebo-controlled clinical trial in support of its petition to FDA seeking Category I status for trolamine salicylate, the active ingredient in Aspercreme ("The Tan Sheet" Jan. 24, 1994, p. 16). The June 12 submission supports the effectiveness of the ingredient as a topical analgesic for the relief of pain and stiffness associated with arthritis, Thompson Med says, and further confirms the results of the two clinical trials that have already been provided to FDA ("The Tan Sheet" May 9, 1994, In Brief)...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS084121

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel